Act Louvika

Ibrutinib

Category:

Chemical

Chemical

Oral

Oral

Dosage form :

Capsules

Doses :

140 mg

Short Description:

Act Louvika contains the active substance ibrutinib. Act Louvika is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia.

Product Introduction

What Act Louvika is and what it is used for

Act Louvika is an anticancer medicine that contains the active substance Ibrutinib. It belongs to a class of medicines called protein kinase inhibitors.

 

What Act Louvika is used for

It is used to treat the following blood cancers in adults:

  • Mantle cell lymphoma (MCL), a type of cancer affecting the lymph nodes, when the disease has come back or has not responded to treatment.
  • Chronic lymphocytic leukaemia (CLL) a type of cancer affecting white blood cells called lymphocytes that also involves the lymph nodes. Act Louvika is used in patients who have not previously been treated for CLL or when the disease has come back or has not responded to treatment.
  • Waldenstrom’s macroglobulinaemia (WM), a type of cancer affecting white blood cells called lymphocytes. It is used in patients who have not previously been treated for WM or when the disease has come back or has not responded to treatment or in patients for whom chemotherapy given together with an antibody is not a suitable therapy.

 

How Act Louvika works

In MCL, CLL and WM, Act Louvika works by blocking Bruton’s tyrosine kinase, a protein in the body that helps these cancer cells grow and survive. By blocking this protein, Act Louvika helps kill and reduce the number of cancer cells. It also slows down the worsening of the cancer.

Sunitinib

Chemical

Chemical

Oral

Oral

Palbociclib

Chemical

Chemical

Oral

Oral

Zoledronic Acid

Chemical

Chemical

Injectable

Injectable